Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

Johns Hopkins Medicine

Status and phase: Completed; Phase 2; Phase 1

Conditions: Precancerous Condition; Cervical Cancer

Treatments: Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00121173

P30CA006973 (U.S. NIH Grant/Contract)

JHOC-03-05-06-02 (Other Identifier)

JHOC-J0323

R21CA105696 (U.S. NIH Grant/Contract)

J0323 CDR0000439494

Details and patient eligibility

About

RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent cervical cancer.

PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in preventing cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.

Full description

OBJECTIVES:

Primary

• Determine the feasibility and toxicity of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine in preventing cervical cancer in patients with human papillomavirus (HPV)-16-positive grade 2 or 3 cervical intraepithelial neoplasia.
• Determine the effect of this vaccine on the histology of cervical tissue specimens from these patients.

Secondary

• Determine changes in lesion size and HPV viral load in patients treated with this vaccine.
• Determine the cellular, humoral, and local tissue immune responses in patients treated with this vaccine.
• Correlate measures of immune response with clinical response in patients treated with this vaccine.
• Correlate measures of immune response in patients treated with this vaccine with those observed in the preclinical model.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

• Phase I: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine subcutaneously once in weeks 0, 4, and 8 in the absence of disease progression or unacceptable toxicity. Patients undergo colposcopy in week 8, 15 and 19 and a therapeutic loop electrosurgical excision procedure (LEEP) in week 15.

Cohorts of patients receive escalating doses of vaccine until the safest dose is determined.

• Phase II: Patients receive vaccine as in phase I but at the safest dose determined in phase I. Patients also undergo colposcopy and LEEP as in phase I.

After completion of the study treatment, patients are followed annually for 15 years.

PROJECTED ACCRUAL: Approximately 150 patients (approximately 12 will be treated in phase I and 25 will be treated in phase II) will be accrued for this study.

Enrollment: 16 patients

Sex: Female

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed cervical intraepithelial neoplasia (CIN2/3)
• Human papillomavirus-16-positive disease

PATIENT CHARACTERISTICS:

• Age: > 18

Other

• Not pregnant
• Immunocompetent

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

16 participants in 3 patient groups

Low dose

Experimental group

Description:

3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals. Genetic (recombinant DNA vaccine)

Treatment:

Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine

Intermediate dose

Experimental group

Description:

3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)

Treatment:

Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine

High dose

Experimental group

Description:

3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)

Treatment:

Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine